

ASX Announcement

29 October 2024

BCAL Diagnostics announces publication in peer-reviewed journal describing the discovery of the technology that underpins BREASTEST®

- Publication in the highly regarded *International Journal of Molecular Sciences*
- The article concludes that:
 - Lipids extracted from blood-plasma can be used as target analytes in the development of an assay to detect early-stage breast cancer
 - A 20-lipid panel generated an AUC of 0.95, sensitivity of 0.91 and specificity of 0.79
- Detection of breast cancer at the early-stage supports BCAL's intended use of BREASTEST® in a screening population
- Peer-reviewed journal publications are an important part of BCAL's commercialisation and regulatory strategy

Breast cancer screening and diagnostic company BCAL Diagnostics Limited (ASX:BDX, 'BCAL' or the 'Company') is pleased to announce that an original research article by BCAL has been published today in the *International Journal of Molecular Sciences*.

The article describes the methodology and results from early discovery work that forms the basis of the technology that underpins BCAL's novel blood test for the detection of early-stage breast cancer, BREASTEST®. The article is titled "Discovery of Plasma Lipids as Potential Biomarkers Distinguishing Breast Cancer Patients from Healthy Controls". The advanced online publication can be found at the following LINK <https://www.mdpi.com/1422-0067/25/21/11559>.

Director of Clinical Research at BCAL and corresponding author, **Simon Preston commented:** *"This publication is an important milestone for the company. BCAL will be the first company to launch a cancer detection test using a proprietary panel of lipids and machine-learning developed diagnostic algorithm. Peer-reviewed publications are a crucial step to gaining academic and commercial validation of new technologies such as ours. A number of publications that illustrate the methodical and step-wise development of BREASTEST® are in process. It is exciting to see the first of these publications now in press."*

Chief Executive Officer, Shane Ryan commented: *"Peer-reviewed publications are a crucial aspect of developing novel technologies like BREASTEST®. The publication provides us with critical support and a strong foundation with which to move forward with the commercialisation of BREASTEST®. Today's publication marks BCAL's first peer publication and a major milestone for BCAL. Several additional peer-reviewed publications are planned for submission by the end of FY 2025 to support market access strategies and global regulatory submissions"*.

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

ENDS

For further information:

Jayne Shaw

Executive Chair
Jshaw@bcaldiagnostics.com

Shane Ryan

Chief Executive Officer
sryan@bcaldiagnostics

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating excellent performance. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/>